Amgen Inc. announced on December 12 an agreement to acquire Horizon Therapeutics plc in the largest healthcare transaction of the year. Amgen will pay $116.50 for each Horizon share, totaling approximately $27.8 billion.
Horizon was advised by Morgan Stanley and JPMorgan Chase & Co. Its legal advisers are Cooley LLP and Matheson LLP.
Amgen’s lead financial adviser is PJT Partners and its financial adviser is Citigroup Inc. Its legal advisers are Sullivan Cromwell LLP and William Fry LLP.
Horizon Therapeutics is an Irish biopharmaceutical company focused on developing medicines to treat rare autoimmune and severe inflammatory diseases. The company’s products are sold mostly in the U.S. Tepezza is used to treat thyroid eye disease, an affliction characterized by progressive inflammation and damage to tissues around the eyes.
Founded in 1980, Amgen is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company discovers, develops, makes and delivers therapeutics in the areas of oncology, cardiovascular, inflammation and neuroscience.
In October 2022, Amgen completed a $3.7 billion deal for ChemoCentryx and its drug to treat a rare immune-system disease. The acquisition of Horizon bolsters Amgen’s lineup of rare immune-disease drugs.
According to the LevinPro HC database, this marks the 137th Biotech transaction of 2022.
